Press release
Urnamai Launches to Revolutionize Legal Workflows with AI Automation Tools for Law Firms
August 7, 2025 - London, UK - Urnamai, a new LegalTech startup, officially launches today with a bold mission to help law firms work faster, smarter and more securely by eliminating time wasted on repetitive manual tasks.
Built for small to mid-sized law firms, Urnamai offers a modern legal AI platform that automates contract drafting, compliance monitoring, meeting protocols and legal playbooks. It integrates directly with tools firms already use, including Microsoft Word, iManage, SharePoint and CRM systems.
"Legal teams are under more pressure than ever. We saw an opportunity to help them reclaim time and focus," said a Urnamai co-founder. "We are not trying to replace lawyers. We are helping them do more of what matters and less of what does not."
The company is currently entering its pilot phase and opening its first funding round aimed at angel investors with an interest in LegalTech, contract automation and AI in law.
Urnamai stands out with a strong focus on ease of use, jurisdiction-specific legal intelligence and built-in GDPR and compliance support. Its Regulatory Watchdog keeps playbooks up to date with real-time legal changes and suggested updates.
The founding team brings a unique blend of startup experience and operational excellence. One co-founder scaled a fast-growing tech company in Sweden while the other optimized operations at hospitals in the UK. Together, they are building tools that are intuitive, impactful and easy to adopt.
Urnamai invites small and mid-sized law firms to join as pilot partners and welcomes strategic angel investors to support the next phase of growth.
Media Contact
Company Name: Urnamai
Contact Person: Seif Hisnawi
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=urnamai-launches-to-revolutionize-legal-workflows-with-ai-automation-tools-for-law-firms]
Phone: +447931535216
City: London
Country: United Kingdom
Website: https://urnamai.com
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Urnamai Launches to Revolutionize Legal Workflows with AI Automation Tools for Law Firms here
News-ID: 4137636 • Views: …
More Releases from ABNewswire
Motor Neuron Disease Clinical Trials, Companies, Therapeutic Assessment, Therapi …
DelveInsight's, "Motor Neuron Disease- Pipeline Insight, 2025" report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in Motor Neuron Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.
DelveInsight reports that the Motor Neuron Disease pipeline involves over 180 key companies actively developing more than 200 investigational…
Metastatic Non-small Cell Lung Cancer Clinical Trials, Companies, Therapeutic As …
DelveInsight's, "PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) - Pipeline Insight, 2025" report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.
DelveInsight reports that the Metastatic Non-Small Cell Lung Cancer pipeline…
SYK Inhibitor Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Appr …
DelveInsight's, "Spleen Tyrosine Kinase (SYK) Inhibitors Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Spleen Tyrosine Kinase (SYK) Inhibitors pipeline landscape. It covers the SYK Inhibitor pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive…
Mild Cognitive Impairment Market: Epidemiology, Therapies, Companies Working, De …
The Mild Cognitive Impairment market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Mild Cognitive Impairment market size from 2020 to 2034.
Emerging therapies for Mild Cognitive Impairment, including LEQEMBI (lecanemab), KISUNLA (donanemab), and others, are anticipated to drive growth in the Mild Cognitive Impairment market in the coming years.
DelveInsight has launched a new report on "Mild Cognitive Impairment - Market…
